TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
HOLD

Pfizer Inc(PFE)

Jul 10, 2008
All of the big pharma have been very disappointing. Now yielding over 7% but doesn't think the dividend is in jeopardy as the cash flow is amazingly strong. Won't be a great investment for another year or so.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$18.03

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 04, 2008
Not cheap enough for him yet. He would have to go over the financial statements. There are a lot of companies in this area that may be of interest in the next few years.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$17.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 11, 2008
Model price has been decreasing over the last 9 months, but not all that much. Thinks it will go down to $15.75 but he sees in setting up as a huge rally in healthcare related stocks in Q4 or Q1 of 09. Has an 86% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.55

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 10, 2008
Pharmaceutical industry in the US has been a disappointment for 2 or 3 years. There is concern about the new drug pipeline. Also a large number of blockbuster drugs are coming off patent for many companies. Also increased competition from generic companies. At 7.2%, the market is telling you it does not believe the dividend is safe.
Photo of David BaskinDavid BaskinUnlock Rating
$17.94

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 09, 2008
Its problem, along with many of the health care companies in the US, is the pipeline. Lipitor, which is a large portion of their revenues, comes off patent next year. Have lots of cash flow but haven't been able to take advantage to develop anything. Would buy Novo-Nordisk (NVO-N) instead.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$18.02

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 05, 2008
From his perspective, it has absolutely technically broken down. Looks like almost everything is going against it. Also, it is likely Democrats will come to power and won't be helpful to the drug companies.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$18.67

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 03, 2008
6.73% dividend. Doesn't see a lot of prospects in their pipeline. Some of their big money makers are in a lot of jeopardy from competition. If you like pharmaceuticals, consider moving into Johnson & Johnson (JNJ-N).
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$19.01

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 02, 2008
Product portfolio continues to undergo greater competition from generics. New products are declining. Still haven't turned the corner. Generics such as Teva Pharmaceutical (TEVA-Q) would be more attractive.
Photo of David GarrityDavid Garrity
No
Unlock Rating
$19.18

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 21, 2008
Candidates in the presidential race have not been positive on pharmaceutical companies. The problem with this company however is the lack of a pipeline. Most of the earnings are coming from some products that are going to go off patent in the next couple of years. Has become more and more expensive to generate new drugs. The dividend could be a potential trap and could be lowered.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$20.01

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 15, 2008
6.5% dividend yield. Cash flows are very strong.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$20.08

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 14, 2008
Recently sold his holdings. A lot of their pipeline is going into generic distribution, which will take a lot of revenue off the top line. Feels the 6% dividend is probably safe.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.06

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 12, 2008
(A Top Pick May 18/07. Down 23%.) Have not proven to be defensive. Most of the major drug companies have more of their larger drugs coming off patent shortly. At this point, downside risk looks pretty limited. 6% plus yield. A Hold.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.91

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 08, 2008
(A Top Pick May 2/07. Down 20%.) Still in his Top 10. His model price is $34.72, a 74% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.97

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 25, 2008
The trouble he has with the big pharmaceuticals is that they are having a terribly hard time reinventing themselves. They all have good yields. The FDA right now is turning the taps off. It is harder and harder to get approval. Would be very cautious on this sector. The one exception is Johnson & Johnson (JNJ-N), which seems to have a better approach than their peers.
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$20.43

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 23, 2008
This has not been a good experience over the last year. Stock has come off pretty sharply. All of the drugs are coming off patent for the big pharmaceuticals. Trading at under 10X earnings and is still earning 35% on its equity and yielding over 6%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$19.88

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 526 to 540 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like